- 询价
- gelatins
- JLC220595
- 上海
- 2025年07月14日
- 人/动物/植物
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 克隆性：
多克隆
- 抗体名：
Anti-EFNA1 antibody
- 适应物种：
人/动物/植物
- 浓度：
0.6 mg/ml
- 保存条件：
-20°C
- 规格：
25 μl/100 μl/200 μl
Cat. No. JLC220595
Package 25 μl/100 μl/200 μl
Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Product overview
Description Anti-EFNA1 rabbit polyclonal antibody
Applications ELISA, IHC
Immunogen Fusion protein of human EFNA1
Reactivity Human, Mouse, Rat
Content 0.6 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Target information
Symbol EFNA1
Full name ephrin-A1
Synonyms B61, EFL1, ECKLG, EPLG1, LERK1, LERK-1, TNFAIP4
Swissprot P20827
Target Background
This gene encodes a member of the ephrin (EPH) family. The ephrins and EPH-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events, especially in the nervous system and in erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. This gene encodes an EFNA class ephrin which binds to the EPHA2, EPHA4, EPHA5, EPHA6, and EPHA7 receptors. Two transcript variants that encode different isoforms were identified through sequence analysis.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验a simple ELISA method to detect human anti-antibody response.
Purification Of Anti Peptide Antibody
antibody that could contribute to staining background. The proportion in each pool varies with the peptide immunogen. The quality of the anti-peptide serum seems to increase with multiple boosts - the first bleed may be feeble.
Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays
standard” laboratory test to diagnose or classify a patient as having APS. This chapter discusses the clinical and laboratory theoretical and technical aspects of aCL and anti-β2GPI antibody assays.
